Skip to main content
SpringerLink
Log in

Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir

  • Case Report
  • Published:
Journal of Infection and Chemotherapy

Abstract

Drug-resistant virus infection has been a major hurdle in the management of human immunodeficiency virus type 1 (HIV-1) infection. Recently, three novel antiretrovirals [raltegravir (RAL), etravirine (ETR), and darunavir (DRV)] were introduced into the market almost simultaneously, and salvage regimens containing these three antiretrovirals have been reported to exhibit strong potency against drug-resistant HIV-1 infection. However, the sustainability of such regimens remains unclear, particularly for patients infected with multidrug-resistant viruses. Here we report a case of super-multidrug-resistant HIV-1 infection which has been successfully controlled by novel combination therapy including RAL, ETR, and DRV for over 2 years, indicating that the novel combination could become an ultimate weapon against drug-resistant HIV infection and could alter the landscape of HIV salvage therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bailey J, Blankson JN, Wind-Rotolo M, Siliciano RF. Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. Curr Opin Immunol. 2004;16:470–6.

    Article  CAS  PubMed  Google Scholar 

  2. de Mendoza C, O Gallego, Soriano V. Mechanisms of resistance to antiretroviral drugs—clinical implications. AIDS Rev. 2002;4:64–82.

    PubMed  Google Scholar 

  3. Kuritzkes DR. HIV resistance: frequency, testing, mechanisms. Top HIV Med. 2007;15:150–4.

    PubMed  Google Scholar 

  4. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261–9.

    Article  CAS  PubMed  Google Scholar 

  5. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–54.

    Article  PubMed  Google Scholar 

  6. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48.

    Article  CAS  PubMed  Google Scholar 

  7. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38.

    Article  CAS  PubMed  Google Scholar 

  8. Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro Rde J, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46:24–31.

    CAS  PubMed  Google Scholar 

  9. Molina JM, Hill A. Darunavir (TMC114): a new HIV-1 protease inhibitor. Expert Opin Pharmacother. 2007;8:1951–64.

    Article  CAS  PubMed  Google Scholar 

  10. Poveda E, de Mendoza C, Martin-Carbonero L, Corral A, Briz V, Gonzalez-Lahoz J, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother. 2007;60:885–8.

    Article  CAS  PubMed  Google Scholar 

  11. Poveda E, Garrido C, de Mendoza C, Corral A, Cobo J, Gonzalez-Lahoz J, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007;60:1409–10.

    Article  CAS  PubMed  Google Scholar 

  12. Damond F, Roquebert B, Benard A, Collin G, Miceli M, Yeni P, et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol. 2007;45:3436–8.

    Article  CAS  PubMed  Google Scholar 

  13. Yao JD, Germer JJ, Damond F, Roquebert B, Descamps D. Plasma load discrepancies between the Roche Cobas Amplicor human immunodeficiency virus type 1 (HIV-1) Monitor version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assays. J Clin Microbiol. 2008;46:834. author reply 834.

    Article  PubMed  Google Scholar 

  14. Schutten M, Peters D, Back NK, Beld M, Beuselinck K, Foulongne V, et al. Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol. 2007;45:1712–7.

    Article  CAS  PubMed  Google Scholar 

  15. Scott LE, Noble LD, Moloi J, Erasmus L, Venter WD, Stevens W. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol. 2009;47:2209–17.

    Article  PubMed  Google Scholar 

  16. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 2010;24(4):503–14.

    Article  CAS  PubMed  Google Scholar 

  17. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49:1441–9.

    Article  CAS  PubMed  Google Scholar 

  18. Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther. 2004;2:147–51.

    Article  CAS  PubMed  Google Scholar 

  19. Wei X, Liang C, Gotte M, Wainberg MA. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. AIDS. 2002;16:2391–8.

    Article  CAS  PubMed  Google Scholar 

  20. Sierra S, Kaiser R, Thielen A, Lengauer T. Genotypic coreceptor analysis. Eur J Med Res. 2007;12:453–62.

    CAS  PubMed  Google Scholar 

  21. Saracino A, Monno L, Punzi G, Cibelli DC, Tartaglia A, Scudeller L, et al. HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples. Virus Res. 2007;130:34–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant for ‘Nation Wide Drug Resistance HIV Surveillance Study in Acutely and Chronically Infected HIV-1 Patients in Japan’ of the Ministry of Health Labor and Welfare in Japan, and by ‘the Clinical Study Group for AIDS Drugs’ of the Japan Health Sciences Foundation. Etravirine was provided by Tibotec for compassionate use; and raltegravir was obtained through the Expanded Access Program by Merck & Co., Inc. (Darmstadt, Germany). Written informed consent was obtained from the presented patient, and the study was approved by the Institutional Review Board at the Institute of Medical Science, The University of Tokyo. The authors declare no conflicts of interests.

Author information

Authors and Affiliations

  1. Division of Infectious Disease, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan

    Hitomi Nakamura, Noriaki Hosoya, Michiko Koga, Takashi Odawara, Tadashi Kikuchi, Ai Kawana-Tachikawa, Toshiyuki Miura & Aikichi Iwamoto

  2. Japan Foundation for AIDS Prevention, Tokyo, Japan

    Naoko Miyazaki

  3. Department of Infectious Diseases and Applied Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Naoko Miyazaki, Tomohiko Koibuchi, Takeshi Fujii & Aikichi Iwamoto

Authors
  1. Hitomi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoko Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noriaki Hosoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michiko Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Odawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tadashi Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomohiko Koibuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ai Kawana-Tachikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takeshi Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshiyuki Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Aikichi Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiyuki Miura.

About this article

Cite this article

Nakamura, H., Miyazaki, N., Hosoya, N. et al. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir. J Infect Chemother 17, 105–110 (2011). https://doi.org/10.1007/s10156-010-0082-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-010-0082-4

Keywords

Search

Navigation